

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 8-K

TRIANGLE PHARMACEUTICALS INC
Form 8-K
January 18, 2002

OMB APPROVAL

OMB Number: 3235-0060
Expires: May 31, 2000
Estimated average burden
hours per response....5.00

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) January 17, 2002

TRIANGLE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

000-21589

56-1930728

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

4 University Place, 4611 University Drive, Durham, North Carolina 27707

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (919) 493-5980

(Former name or former address, if changed since last report)

Item 5. Other Events and Regulation FD Disclosure.

On January 17, 2002, Triangle Pharmaceuticals, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

Item 7. Financial Statements and Exhibits.

(c) Exhibits. The following document is incorporated by reference to this Report:

99.1 Press release dated January 17, 2002

SIGNATURES

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Triangle Pharmaceuticals, Inc.

(Registrant)

January 18, 2002

/s/ Robert F. Amundsen, Jr.

Date

(Signature)

Name: Robert F. Amundsen, Jr.

Title: Executive Vice President & Chief Financial Officer